S Vigili de Kreutzenberg1, G Ceolotto1, A Cattelan1, E Pagnin1, M Mazzucato1, P Garagnani2, V Borelli2, M G Bacalini3, C Franceschi2, G P Fadini4, A Avogaro5. 1. Department of Medicine - DIMED, University of Padova, Italy. 2. Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Italy. 3. Interdepartmental Centre "L. Galvani" for Bioinformatics, Biophysics and Biocomplexity, University of Bologna, Italy. 4. Department of Medicine - DIMED, University of Padova, Italy; Venetian Institute of Molecular Medicine - VIMM, Padova, Italy. 5. Department of Medicine - DIMED, University of Padova, Italy; Venetian Institute of Molecular Medicine - VIMM, Padova, Italy. Electronic address: angelo.avogaro@unipd.it.
Abstract
BACKGROUND AND AIMS: Prediabetes increases cardiovascular risk and is associated with excess mortality. In preclinical models, metformin has been shown to exert anti-ageing effects. In this study, we sought to assess whether metformin modulates putative effector longevity programs in prediabetic subjects. METHODS AND RESULTS: In a randomized, single-blind, placebo-controlled trial, 38 prediabetic subjects receivedmetformin (1500 mg/day) or placebo for 2 months. At baseline and after treatment, we collected anthropometric and metabolic parameters. Gene and protein levels of SIRT1, mTOR, p53, p66Shc, SIRT1 activity, AMPK activation, telomere length, and SIRT1 promoter chromatin accessibility were determined in peripheral blood mononuclear cells (PBMCs). Plasma N-glycans, non-invasive surrogate markers of ageing, were also analysed. Compared to baseline, metformin significantly improved metabolic parameters and insulin sensitivity, increased SIRT1 gene/protein expression and SIRT1 promoter chromatin accessibility, elevated mTOR gene expression with concomitant reduction in p70S6K phosphorylation in subjects' PBMCs, and modified the plasma N-glycan profile. Compared to placebo, metformin increased SIRT1 protein expression and reduced p70S6K phosphorylation (a proxy of mTOR activity). Plasma N-glycans were also favourably modified by metformin compared to placebo. CONCLUSION: In individuals with prediabetes, metformin ameliorated effector pathways that have been shown to regulate longevity in animal models. ClinicalTrials. gov identifier: NCT01765946 - January 2013.
RCT Entities:
BACKGROUND AND AIMS: Prediabetes increases cardiovascular risk and is associated with excess mortality. In preclinical models, metformin has been shown to exert anti-ageing effects. In this study, we sought to assess whether metformin modulates putative effector longevity programs in prediabetic subjects. METHODS AND RESULTS: In a randomized, single-blind, placebo-controlled trial, 38 prediabetic subjects received metformin (1500 mg/day) or placebo for 2 months. At baseline and after treatment, we collected anthropometric and metabolic parameters. Gene and protein levels of SIRT1, mTOR, p53, p66Shc, SIRT1 activity, AMPK activation, telomere length, and SIRT1 promoter chromatin accessibility were determined in peripheral blood mononuclear cells (PBMCs). Plasma N-glycans, non-invasive surrogate markers of ageing, were also analysed. Compared to baseline, metformin significantly improved metabolic parameters and insulin sensitivity, increased SIRT1 gene/protein expression and SIRT1 promoter chromatin accessibility, elevated mTOR gene expression with concomitant reduction in p70S6K phosphorylation in subjects' PBMCs, and modified the plasma N-glycan profile. Compared to placebo, metformin increased SIRT1 protein expression and reduced p70S6K phosphorylation (a proxy of mTOR activity). Plasma N-glycans were also favourably modified by metformin compared to placebo. CONCLUSION: In individuals with prediabetes, metformin ameliorated effector pathways that have been shown to regulate longevity in animal models. ClinicalTrials. gov identifier: NCT01765946 - January 2013.
Authors: María Del Carmen Rubio Osornio; Verónica Custodio Ramírez; Daniela Calderón Gámez; Carlos Paz Tres; Karla G Carvajal Aguilera; Bryan V Phillips Farfán Journal: Cell Mol Neurobiol Date: 2018-08-21 Impact factor: 5.046
Authors: Robin Bonomi; Vadim Popov; Maxwell T Laws; David Gelovani; Anjoy Majhi; Aleksandr Shavrin; Xin Lu; Otto Muzik; Nashaat Turkman; Renshyan Liu; Thomas Mangner; Juri G Gelovani Journal: J Med Chem Date: 2018-08-13 Impact factor: 7.446
Authors: Michael N Sack; Frej Y Fyhrquist; Outi J Saijonmaa; Valentin Fuster; Jason C Kovacic Journal: J Am Coll Cardiol Date: 2017-07-11 Impact factor: 24.094